Potent inhibitor of cyclin-dependent kinase (cdk) 1, 2 and 9 (IC50
values are 16, 6 and 20 nM respectively). Exhibits antiproliferative activity in human tumor cell lines. Blocks cell cycling at G2
-M, S and G1
phases; reduces the proportion of actively cycling cells in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of AstraZeneca UK Ltd.
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2 and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Byth et al.
Mol.Cancer Ther., 2009;8:1856
The citations listed below are publications that use Tocris products. Selected citations for AZD 5438 include:
Showing Results 1 - 2 of 2